SCHEMBL26109983

SCHEMBL26109983

CCCCCCCCCC/C(=C/C(=O)O)CCCCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.56
PPARG P37231 7/20 0.56
PPARD Q03181 7/20 0.56
PPARA Q07869 7/20 0.56
HDAC11 Q96DB2 5/20 0.56
TSHR P16473 4/20 0.56
PTPN1 P18031 3/20 0.56
FABP4 P15090 3/20 0.56
ALDH1A1 P00352 2/20 0.56
TLR2 O60603 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
ALOX15 P16050 2/20 0.56
HSD17B10 Q99714 2/20 0.56
SLC22A6 Q4U2R8 1/20 0.56
SLC22A8 Q8TCC7 1/20 0.56
MEN1 O00255 1/20 0.56
ESR1 P03372 1/20 0.56
PDE4A P27815 1/20 0.56
KMT2A Q03164 1/20 0.56
PDE3A Q14432 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16829756 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL31259314 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL30548814 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL26133514 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL300878 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL16023970 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL27153404 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL30548790 0.98 GPR84 (0.54) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL9860409 0.98 GPR84 (0.54) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL9860411 0.98 GPR84 (0.54) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214925-A1 CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE CARCELL BIOPHARMA LTD. (CN) 2025-07-03 US disclosed
EP-4488259-A1 CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE Carcell Biopharma Ltd. (CN) 2025-01-08 EP disclosed
WO-2023186167-A1 CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE 科镁信(上海)生物医药科技有限公司 2023-10-05 WO disclosed
WO-2023186171-A1 CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE 科镁信(上海)生物医药科技有限公司 2023-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214925-A1 CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE LIPA, LIPC, ABCB4 GPR84 3849/4885PPARG 908/4885PPARD 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.